DXCM congressional trades
DexCom, Inc. (DXCM) appears in 10 congressional disclosure rows from 5 members of Congress in 2025–2026 periodic reports: 4 purchases and 6 sales, with trade dates from Dec 31, 2024 to May 7, 2026. Jefferson Shreve reported the most, with 3 rows. The median gap between trade date and filing date is 23 days, and every trade was reported within 45 days.
Rows keep the disclosed owner and amount range. This is a record of reported transactions, not a live DXCM portfolio or a trading signal.
- 10
- 5
- 4 / 6
- $299K – $810K
- sum of reported ranges
- 2026-05-07
Verified DXCM congressional disclosures
Parsed from official House Clerk and Senate eFD filings. This snapshot contains 4 purchases and 6 sales. Reported owners: Spouse, Joint, Self. Transaction dates run from 2024-12-31 to 2026-05-07.
| Politician | Trade date | Asset | Type | Owner | Amount | Filing |
|---|---|---|---|---|---|---|
| Tina Smith | DexCom, Inc. - Common Stock | Sale | Spouse | $100,001 - $250,000 | #3f315067-5f69-42b3-b32d-063ce735957b Filed 2026-05-10 | |
| Tina Smith | DexCom, Inc. - Common Stock | Sale | Spouse | $100,001 - $250,000 | #3f315067-5f69-42b3-b32d-063ce735957b Filed 2026-05-10 | |
| John Boozman | Dexcom Inc | Purchase | Joint | $1,001 - $15,000 | #135ebfe9-099e-4d58-ba46-f739b90d61da Filed 2026-02-15 | |
| Robert Bresnahan | DexCom, Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20030482 Filed 2025-06-09 | |
| Jefferson Shreve | DexCom, Inc. - Common Stock | Sale | Self | $15,001 - $50,000 | #20030387 Filed 2025-06-22 | |
| Jefferson Shreve | DexCom, Inc. - Common Stock | Purchase | Self | $15,001 - $50,000 | #20030387 Filed 2025-06-22 | |
| Robert Bresnahan | DexCom, Inc. - Common Stock | Sale | Self | $1,001 - $15,000 | #20030238 Filed 2025-04-28 | |
| Jefferson Shreve | DexCom, Inc. - Common Stock | Sale | Self | $15,001 - $50,000 | #20030231 Filed 2025-05-08 | |
| Robert Bresnahan | DexCom, Inc. - Common Stock | Purchase | Self | $1,001 - $15,000 | #20029034 Filed 2025-03-27 | |
| Kevin Hern | DexCom, Inc. - Common Stock | Sale | Joint | $50,001 - $100,000 | #20026597 Filed 2025-01-15 |
A filing can describe the member, a spouse, a dependent, or a joint asset. Amounts are statutory ranges, not execution prices. See how to read congressional stock-trade disclosures before treating a delayed row as a trading signal.
DXCM disclosures by member
| Member | Rows | Buys | Sells | Last trade |
|---|---|---|---|---|
| Jefferson Shreve's DXCM trades | 3 | 1 | 2 | 2025-05-12 |
| Robert Bresnahan's DXCM trades | 3 | 2 | 1 | 2025-05-15 |
| Tina Smith | 2 | 0 | 2 | 2026-05-07 |
| John Boozman | 1 | 1 | 0 | 2026-01-26 |
| Kevin Hern | 1 | 0 | 1 | 2024-12-31 |
How long disclosure took
Days from trade date to filing date for 10 rows. The STOCK Act allows 30 days from notification and no more than 45 days from the trade. A late row is a timing fact, not evidence of wrongdoing.
- 0–15 days
- 3
- 16–30 days
- 4
- 31–45 days
- 3
- Over 45 days
- 0
- Median / longest
- 23d / 45d
Source documents
8 House Clerk and Senate eFD periodic transaction reports, newest first. Each link opens the official filing.
- #3f315067-5f69-42b3-b32d-063ce735957bFiled 2026-05-10 · 2 rows
- #135ebfe9-099e-4d58-ba46-f739b90d61daFiled 2026-02-15 · 1 row
- #20030387Filed 2025-06-22 · 2 rows
- #20030482Filed 2025-06-09 · 1 row
- #20030231Filed 2025-05-08 · 1 row
- #20030238Filed 2025-04-28 · 1 row
- #20029034Filed 2025-03-27 · 1 row
- #20026597Filed 2025-01-15 · 1 row
What DXCM filings don’t tell you
A disclosure row records a trade date, an amount bracket, and who owned the asset. It does not say why the trade was made, whether the position is still held, or anything about the business behind the ticker: revenue trends, margins, balance-sheet risk, or valuation. Those answers are in company filings, not congressional ones.
- DexCom, Inc. financials and filings
Audited SEC figures, what moves DXCM, and primary sources.
To work through a company yourself, use our stock research checklist. Members get the full version of that work: one sourced investment call a month, with the numbers and the risks that would change the view.
Members-only research
What members are reading this month
- NVIDIA’s growth has a financing bill
Sales up about 18% on the prior quarter, receivables up about 55%, supply commitments at $279 billion. What NVIDIA’s financing bill means for the price you pay.
- Citadel bought the AI fire sale. The seller had run out of time.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchRelated research
DXCM congressional trades: FAQ
Who in Congress traded DXCM?
House Clerk and Senate eFD periodic reports for 2025 and 2026 contain 10 verified DXCM rows from 5 members: Jefferson Shreve, John Boozman, Kevin Hern, Robert Bresnahan, and Tina Smith. Image-only filings are excluded, and this is not a live brokerage statement.
Does this page show current DXCM holdings?
No. STOCK Act filings disclose reportable transactions after the fact, usually within 45 days, as amount ranges and owners. They do not prove a current position, an exact share count, or why the trade happened.
Why are DXCM amounts shown as ranges?
Congressional periodic transaction reports use statutory value bands such as $100,001 - $250,000; $1,001 - $15,000; $15,001 - $50,000; $50,001 - $100,000. Yield Theory keeps those ranges instead of inventing a midpoint, exact trade size, or return.
How complete is DXCM congressional-trade coverage?
This snapshot covers every machine-readable House and Senate periodic transaction report for 2025 and 2026 (177 members). Image-only House filings and paper Senate filings are not included, so missing rows are not proof that no other lawmaker traded DXCM.
Yield Theory is not affiliated with any elected official. This page uses the 2025–2026 House Clerk and Senate eFD periodic report snapshot generated 2026-10-09. It is not a complete lifetime portfolio, a performance track record, or investment advice.
A disclosure is not a thesis.
This page shows who reported DXCM and in what range. Membership is the monthly sourced call, plus a five-minute check when the evidence moves. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included